Purpose: A novel device (sleeve) has been developed that attaches to compatible autoinjectors and is designed to improve the patient experience, particularly for those with limited manual dexterity. This study was designed to explore whether user experience is improved when using the Enbrel MyClic autoinjector in conjunction with the sleeve. The Enbrel MyClic autoinjector contains etanercept (Enbrel), a biologic drug that patients self-administer subcutaneously for the treatment of rheumatoid arthritis (RA).

Patients And Methods: Twenty-four adult patients (16 female) with RA and varying degrees of manual dexterity impairment took part in this user study. Written informed consent was supplied by each patient prior to performing the study. They each performed two simulated injections into skin pads, one with the Enbrel MyClic alone and the other with the Enbrel MyClic + sleeve. Following the simulated injections, participants answered questions about their experience of using the sleeve and rated the following on a scale of 1 (poor experience) to 7 (optimal experience): overall use; ease of preparation; ease of administration; ease of learning to use; look, feel and size of the device; overall experience.

Results: Participants rated the Enbrel MyClic + sleeve more highly than the Enbrel MyClic alone for overall use, ease of administration, feel, size and overall experience. Participants with severe dexterity impairment (n = 12) were more likely to rate these features as better with the sleeve in place than those with mild dexterity impairment (n = 10). Three-quarters of participants said they would request the sleeve if it became available and all said that they would recommend it to others. The main benefits cited by participants were better grip and a better feeling of control.

Conclusion: Addition of the sleeve improved patients' experience of using the Enbrel MyClic. The benefits of the sleeve outweighed any inconvenience associated with the additional steps needed to prepare the device.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6818675PMC
http://dx.doi.org/10.2147/MDER.S216649DOI Listing

Publication Analysis

Top Keywords

enbrel myclic
32
dexterity impairment
12
enbrel
9
sleeve
9
addition sleeve
8
myclic
8
rheumatoid arthritis
8
manual dexterity
8
myclic autoinjector
8
simulated injections
8

Similar Publications

Introduction: Etanercept is effective in the management of rheumatoid arthritis (RA) and can be self-administered via an auto-injector. While these devices are generally well accepted, some patients are not comfortable with the process of self-administration; this has been cited as a reason for discontinuation of biologic treatment. Alternative routes of administration (e.

View Article and Find Full Text PDF

Purpose: A novel device (sleeve) has been developed that attaches to compatible autoinjectors and is designed to improve the patient experience, particularly for those with limited manual dexterity. This study was designed to explore whether user experience is improved when using the Enbrel MyClic autoinjector in conjunction with the sleeve. The Enbrel MyClic autoinjector contains etanercept (Enbrel), a biologic drug that patients self-administer subcutaneously for the treatment of rheumatoid arthritis (RA).

View Article and Find Full Text PDF
Article Synopsis
  • Imraldi™ is a newly approved biosimilar of the TNF monoclonal antibody adalimumab, designed for treating inflammatory conditions, and it features a unique autoinjector design.
  • A study surveyed 101 nurses and 151 patients in the UK and Germany to compare their preferences for Imraldi against Humira and Enbrel MyClic autoinjectors.
  • Results indicated a strong preference for Imraldi, with 85% of nurses and 78% of patients favoring it over Humira, and 86% of nurses and 79% of patients preferring it over Enbrel MyClic, primarily due to its ease of use and button-free design.
View Article and Find Full Text PDF

Patients' and nurses' preferences for autoinjectors for rheumatoid arthritis: results of a European survey.

Patient Prefer Adherence

August 2018

Sandoz International GmbH, Holzkirchen, Germany.

Article Synopsis
  • A survey was conducted with 200 rheumatoid arthritis patients and 100 nurses across five countries to compare preferences for four different autoinjectors used for subcutaneous medication delivery.
  • Results showed that both patients and nurses found the SensoReady autoinjector to be easier to use than other devices, with features like an easy grip, buttonless injection, and a visual feedback window contributing to this preference.
  • An overwhelming majority of respondents (81% of patients and 90% of nurses) would recommend the SensoReady autoinjector to new patients, highlighting its convenience and effectiveness.
View Article and Find Full Text PDF

Introduction: Brenzys was developed as an etanercept biosimilar of Enbrel. The aim of this study was to assess preference and perceived ease of use for the new Brenzys autoinjector compared to the currently available marketed Enbrel MYCLIC autoinjector (Australia) and Enbrel SureClick autoinjector (Canada) for the treatment of rheumatoid arthritis (RA). Because RA affects manual dexterity, ease of use of an autoinjector is a particularly important consideration in developing effective self-delivery of long-term courses of therapy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!